Context Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Context Therapeutics R&D Spending Growth & History (CNTX)
Context Therapeutics's r&d spending was $31.9M for fiscal 2025.
View full Context Therapeutics company overviewContext Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $31.9M | $9.2M | +40.33% |
| 2024 | 2024-12-31 | $22.7M | $4.9M | +27.66% |
| 2023 | 2023-12-31 | $17.8M | $10.7M | +150.77% |
| 2022 | 2022-12-31 | $7.1M | $3.3M | +86.36% |
| 2021 | 2021-12-31 | $3.8M | $2.2M | +131.80% |
| 2020 | 2020-12-31 | $1.6M | — | — |
Context Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.5M | $4.7M | +60.01% |
| Q1 2026 | 2026-03-31 | $7.0M | $3.6M | +102.58% |
| Q4 2025 | 2025-12-31 | $11.8M | $9.3M | +370.17% |
| Q3 2025 | 2025-09-30 | $8.7M | −$8.1M | −48.16% |
| Q2 2025 | 2025-06-30 | $7.8M | $6.4M | +465.56% |
| Q1 2025 | 2025-03-31 | $3.5M | $1.5M | +75.50% |
| Q4 2024 | 2024-12-31 | $2.5M | −$2.8M | −52.50% |
| Q3 2024 | 2024-09-30 | $16.8M | $12.3M | +275.13% |
| Q2 2024 | 2024-06-30 | $1.4M | −$2.1M | −59.99% |
| Q1 2024 | 2024-03-31 | $2.0M | −$2.6M | −56.49% |
| Q4 2023 | 2023-12-31 | $5.3M | $3.2M | +147.19% |
| Q3 2023 | 2023-09-30 | $4.5M | $2.4M | +115.89% |
| Q2 2023 | 2023-06-30 | $3.5M | $1.9M | +128.11% |
| Q1 2023 | 2023-03-31 | $4.5M | $3.2M | +235.53% |
| Q4 2022 | 2022-12-31 | $2.1M | $851,230 | +65.80% |
| Q3 2022 | 2022-09-30 | $2.1M | $1.3M | +180.90% |
| Q2 2022 | 2022-06-30 | $1.5M | $184,142 | +13.81% |
| Q1 2022 | 2022-03-31 | $1.4M | $912,756 | +208.04% |
| Q4 2021 | 2021-12-31 | $1.3M | — | — |
| Q3 2021 | 2021-09-30 | $739,598 | $270,927 | +57.81% |
| Q2 2021 | 2021-06-30 | $1.3M | — | — |
| Q1 2021 | 2021-03-31 | $438,739 | — | — |
| Q3 2020 | 2020-09-30 | $468,671 | — | — |
Context Therapeutics r&d spending trends
Over the last five fiscal years, Context Therapeutics's r&d spending increased from $1.6M to $31.9M, a change of $30.2M. The latest reported quarter, Q2 2026, shows $12.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Context Therapeutics source filings ↗